Acuta Capital Partners, LLC In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Acuta Capital Partners, LLC reported 31 stock positions worth $118.6 million . Its top holding was Ocular Therapeutix (OCUL) at 16.0% of the portfolio, followed by Enliven Therapeutics (ELVN, 7.8% ) and Vaxcyte (PCVX, 7.0% ). Compared with Q1 2024, it opened 8 new positions, sold out of 9, added to 12 and reduced 9. The biggest buy was Enliven Therapeutics (ELVN, shares +0% ) and the biggest sale an exit from Applied Therapeutics (APLT).
Location REDWOOD CITY, CA
CIK 0001582844
Portfolio Value $118.6M (Q2 2024) Holdings 31 stocks · $118.6M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q1 2024 OCUL Ocular Therapeutix Inc. 2,771,130 $19.0M Add +5.2% ELVN Enliven Therapeutics Inc. 397,698 $9.3M Add +0.4% PCVX Vaxcyte Inc. 110,400 $8.3M Add +5.3% DYN Dyne Therapeutics Inc. 212,500 $7.5M Add +15.2% PRAX Praxis Precision Medicines I 164,431 $6.8M Add +1.3% CRNX Crinetics Pharmaceuticals Inc. 135,141 $6.1M Add +72.4% RCKT Rocket Pharmaceuticals Inc. 250,370 $5.4M Reduce -23.4% TSHA Taysha Gene Therapies Inc. 2,330,937 $5.2M Reduce -30.1% RVMD Revolution Medicines Inc. 133,000 $5.2M Reduce -7.5% INSM Insmed Inc. 72,100 $4.8M Add +16.8% SRPT Sarepta Therapeutics Inc. 27,500 $4.3M Reduce -57.1% TRML Tourmaline Bio Inc. 269,614 $3.5M Add +3.3% AGIO Agios Pharmaceuticals Inc. 78,700 $3.4M Add +42.4% KURA Kura Oncology Inc. 163,000 $3.4M Add +81.1% MERSANA THERAPEUTICS INC 1,663,000 $3.3M Reduce -23.2% CRBP Corbus Pharmaceuticals Holdi 64,500 $2.9M New WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC 1,849,402 $2.7M No change VRDN Viridian Therapeutics Inc. 199,433 $2.6M No change TERN Terns Pharmaceuticals Inc. 369,280 $2.5M Reduce -20.6% MREO Mereo Biopharma Group PL-ADR 677,000 $2.4M Add +70.2% ACLX Arcellx Inc. 42,200 $2.3M Add +22.3% BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II 177,836 $1.8M New ARGX Argenx SE - ADR 4,000 $1.7M New TRVI Trevi Therapeutics Inc. 260,000 $775K New CELC Celcuity Inc. 45,000 $737K New ORIC Oric Pharmaceuticals Inc. 96,000 $679K Reduce -7.7% PLRX Pliant Therapeutics Inc. 46,200 $497K New RAPP Rapport Therapeutics Inc. 20,000 $465K New NAMS Newamsterdam Pharma Co. NV 22,500 $432K New CYPH Cypherpunk Technologies Inc. filed as LEAP THERAPEUTICS INC 195,000 $382K Reduce -44.9% CLRB Cellectar Biosciences Inc. 70,500 $176K Reduce -50.9%
Options reported separately and not counted above: SVRA puts ($101K).
Other holdings (1): bonds, preferreds, convertibles and warrants · $15K (not counted above) Security Class Shares / Principal Value Change NUVB.WS Nuvation Bio Inc. -CW27 *W EXP 02/10/202 90,832 $15K No change
Total filed on the 13F, all lines: $118.6M.
Portfolio Sells Q1 2024 → Q2 2024 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2024 % Of Portfolio Change To Portfolio ▲ APLT Applied Therapeutics Inc. Sold out 0.00% −3.50 MERSANA THERAPEUTICS INC Reduce -23.2% 2.82% −3.48 IRON Disc Medicine Inc. Sold out 0.00% −3.11 CLDX Celldex Therapeutics Inc. Sold out 0.00% −2.97 HLVX Hillevax Inc. Sold out 0.00% −2.71 IMVT Immunovant Inc. Sold out 0.00% −1.94 TSHA Taysha Gene Therapies Inc. Reduce -30.1% 4.40% −1.81 SRPT Sarepta Therapeutics Inc. Reduce -57.1% 3.66% −1.73 VSTM Verastem Inc. Sold out 0.00% −1.59 RCKT Rocket Pharmaceuticals Inc. Reduce -23.4% 4.54% −1.18 LYRA Lyra Therapeutics Inc. Sold out 0.00% −0.70 RARE Ultragenyx Pharmaceutical Inc. Sold out 0.00% −0.61 ITCI Intra-Cellular Therapies Inc. Sold out 0.00% −0.60 ORIC Oric Pharmaceuticals Inc. Reduce -7.7% 0.57% −0.36 CYPH Cypherpunk Technologies Inc. Reduce -44.9% 0.32% −0.29 CLRB Cellectar Biosciences Inc. Reduce -50.9% 0.15% −0.22 TERN Terns Pharmaceuticals Inc. Reduce -20.6% 2.12% +0.14 RVMD Revolution Medicines Inc. Reduce -7.5% 4.35% +1.34
Portfolio Buys Q1 2024 → Q2 2024 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2024 % Of Portfolio Change To Portfolio ▼ ELVN Enliven Therapeutics Inc. Add +0.4% 7.84% +3.31 INSM Insmed Inc. Add +16.8% 4.07% +2.98 DYN Dyne Therapeutics Inc. Add +15.2% 6.32% +2.92 CRNX Crinetics Pharmaceuticals Inc. Add +72.4% 5.10% +2.72 CRBP Corbus Pharmaceuticals Holdi New 2.46% +2.46 PCVX Vaxcyte Inc. Add +5.3% 7.03% +2.38 AGIO Agios Pharmaceuticals Inc. Add +42.4% 2.86% +1.81 KURA Kura Oncology Inc. Add +81.1% 2.83% +1.58 BBOT Bridgebio Oncology Therapeut New 1.53% +1.53 ARGX Argenx SE - ADR New 1.45% +1.45 MREO Mereo Biopharma Group PL-ADR Add +70.2% 2.05% +1.20 TRVI Trevi Therapeutics Inc. New 0.65% +0.65 CELC Celcuity Inc. New 0.62% +0.62 PLRX Pliant Therapeutics Inc. New 0.42% +0.42 ACLX Arcellx Inc. Add +22.3% 1.96% +0.40 OCUL Ocular Therapeutix Inc. Add +5.2% 15.98% +0.40 RAPP Rapport Therapeutics Inc. New 0.39% +0.39 NAMS Newamsterdam Pharma Co. NV New 0.36% +0.36 PRAX Praxis Precision Medicines I Add +1.3% 5.73% −0.70 TRML Tourmaline Bio Inc. Add +3.3% 2.92% −0.96
Options Activity Q1 2024 → Q2 2024 Security Type Change vs Q1 2024 Underlying Shares Value ▼ SVRA Savara Inc. put New 250 $101K
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 23 $143.5M PRAX, WHWK, TNGX, STRO, AVBP Q1 2026 26 $140.6M PRAX, TERN, WHWK, TNGX, DRUG Q4 2025 29 $147.3M TERN, PRAX, CDTX, OCUL, WHWK Q3 2025 27 $96.8M OCUL, CDTX, TRML, WHWK, INSM Q2 2025 27 $71.6M OCUL, CDTX, WHWK, SLNO, TRML Q1 2025 33 $86.2M OCUL, INSM, TRML, WHWK, ELVN Q4 2024 38 $99.4M OCUL, INSM, TRML, CRNX, ELVN Q3 2024 40 $123.5M PCVX, OCUL, TRML, INSM, ELVN Q2 2024 31 $118.6M OCUL, ELVN, PCVX, DYN, PRAX Q1 2024 32 $153.9M OCUL, PRAX, MERSANA THERAPEUTICS INC, TSHA, RCKT